Latest news with #Graves'
Yahoo
5 days ago
- Business
- Yahoo
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, August 7 @ 4:30 p.m. ET Domestic: 1 833-470-1428 International: 1 404-975-4839 Access Code: 899803 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call. The webcast will be archived on the Investor Relations section of About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. All of the company's drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Investors:Gayathri DiwakarHead of Investor Relationsgdiwakar@ (858) 345-6340 Media: Natalie BadilloHead of Corporate Communications nbadillo@ (858) 345-6075
Business Upturn
30-06-2025
- Business
- Business Upturn
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
Long-term efficacy and safety data on PALSONIFY TM (paltusotine) in acromegaly to be presented, including evidence of both biochemical and symptom control with a well-tolerated safety profile in patients switching treatments and those not previously pharmacologically treated Atumelnant Phase 2 trial results in congenital adrenal hyperplasia (CAH) to be featured in oral presentation Data from early-stage development program in Graves' hyperthyroidism and orbitopathy also to be featured SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced eight abstracts from its novel clinical development programs, including oral presentations featuring its lead investigational drug candidate, PALSONIFY™ (paltusotine)* and investigational candidate atumelnant, will be presented at the Endocrine Society's Annual Meeting, ENDO 2025, July 12-15, 2025, in San Francisco, California. 'ENDO 2025 will be an incredibly meaningful moment for Crinetics in our mission to be the premier endocrine-focused global pharmaceutical company,' said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics. 'For our lead investigational candidate PALSONIFY for acromegaly, we are excited to present long-term data that continue to support the durable, consistent response profile it has shown in earlier pivotal trials. Additionally, compelling Phase 2 trial results from atumelnant in CAH and new data from one of our early-stage development programs demonstrate that the Crinetics pipeline can address significant unmet needs.' Four abstracts will report results from the PALSONIFY development program, including an oral presentation featuring open-label extension data from the registrational Phase 3 PATHFNDR trials. This presentation will highlight long-term efficacy, safety, and symptom control in people with acromegaly who switched from injectable somatostatin receptor ligands (SRLs) to once-daily oral PALSONIFY. In addition, Crinetics will present three poster presentations: one evaluating symptom stability in acromegaly, one analyzing patient-reported outcomes from both PATHFNDR-1 and PATHFNDR-2 and another on PATHFNDR-2 open-label extension data. Together, these abstracts show PALSONIFY continues to be well tolerated, while providing consistent biochemical and symptomatic disease control. Crinetics will also present three abstracts from its atumelnant clinical development program, including an oral presentation of Phase 2 trial results in congenital adrenal hyperplasia (CAH). Additional presentations focus on reduction of adrenal volume and rapid and sustained reductions in potent 11-oxygenated androgens, a novel biomarker, in Phase 2 trial participants. Beyond its two lead programs, Crinetics will present new data from its early-stage pipeline, including data from CRN12755 for Graves' hyperthyroidism and orbitopathy. Additional presentation details are shown below. All times are PT: *The U.S. Food and Drug Administration recently conditionally approved PALSONIFY as the trade name for paltusotine, our once-daily, oral investigational candidate for acromegaly. PALSONIFY™ (paltusotine) Presentations Title: Paltusotine Results in Improved Symptom Stability in Biochemically Controlled Acromegaly Authors: David Clemmons, MD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P34 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (Except Cushing) II – ENDOExpo Poster Area: SUN-043 Title: Effects of Paltusotine Treatment on Patient-Reported Symptoms of Acromegaly in Phase 3 Randomized Placebo-Controlled Studies (PATHFNDR-2 and PATHFNDR-1) Authors: Avery A. Rizio, PhD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P34 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (Except Cushing) II – ENDOExpo Poster Area: SUN-052 Title: Disease Control in Patients With Acromegaly Switching From Injected Somatostatin Receptor Ligands to Once-Daily Oral Paltusotine: Interim Results of the PATHFNDR-1 Open-Label Extension Authors: Beverly M. K. Biller, MD et. al. Date/Time: July 13, 2:45-3:00 PM Location: Session OR12-07 – Neuroendocrinology and Pituitary: Management of Pituitary Disorders – Room 201 Title: Once-Daily Oral Paltusotine in the Treatment of Patients With Biochemically Uncontrolled Acromegaly: Interim Results of the PATHFNDR-2 Open-Label Extension Authors: Monica R. Gadelha, MD, PhD et. al. Date/Time: July 14, 12:00–1:30 PM Location: Session P77 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (except Cushing) III – ENDOExpo: Poster Area; MON-069 Atumelnant Presentations Title: Reductions in Adrenal Volume in Patients With Congenital Adrenal Hyperplasia Receiving Once-Daily Oral Atumelnant (CRN04894): Interim Results From a 12-Week, Phase 2, Open-Label Study Authors: Tania A.S.S. Bachega, MD, PhD et. al. Date/Time: July 12, 12:15-1:45 PM Location: Session P18 – Adrenal (Excluding Mineralocorticoids): Adrenal Insufficiency and CAH I – ENDOExpo Poster Area: SAT-452 Title: Once-Daily Oral Atumelnant (CRN04894) Induces Rapid, Substantial, and Sustained Reductions of Androstenedione and 17‑Hydroxyprogesterone in Adults With Classical Congenital Adrenal Hyperplasia: Interim Results From a 12-Week, Phase 2, Open-Label Study Authors: Umasuthan Srirangalingam, MD, PhD et. al. Date/Time: July 12, 2:30-2:45 PM Location: Session OR07-06 – Adrenal (Excluding Mineralocorticoids): All About Congenital Adrenal Hyperplasia and Adrenal Insufficiency – Room 204 Title: -Rapid and Sustained Reduction of 11-Oxygenated Androgens in Adults With Classic Congenital Adrenal Hyperplasia Following Once-Daily Oral Atumelnant (CRN04894): Results From a 12-Week, Phase 2, Open-Label Study Authors: Nicole Reisch, MD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P55 – Adrenal (Excluding Mineralocorticoids): Adrenal Insufficiency and CAH II – ENDOExpo Poster Area: SUN-438 Early-Stage Pipeline Presentations Title: Discovery and Characterization of an Orally Bioavailable Nonpeptide Thyroid Stimulating Hormone Receptor (TSHR) Antagonist for the Treatment of Graves' Disease and Thyroid Eye Disease Authors: Eulalia A. Coutinho, PhD et. al. Date/Time: July 14, 12:00-1:30 PM Location: Session P92 – Thyroid Biology and Disease: Benign Thyroid Disorders (Auto-Immune) II – ENDOExpo Poster Area: MON-365 Crinetics Sponsored Science & Innovation Theaters Title: Optimizing Long-Term Control in Acromegaly: Key to Improved Patient Outcomes Presenters: Shlomo Melmed, MB ChB; Christian J. Strasburger, MD Date/Time: July 14, 9:30 AM-10:30 AM Location: Theater 1 Title: Navigating the Complexities & Challenges of Acromegaly Management Presenters: Lisa B. Nachtigall, MD; Laurence Katznelson, MD; Scott Struthers, PhD Date/Time: July 14, 12:30 PM -1:30 PM Location: Theater 1 About PALSONIFY™ (Paltusotine) Crinetics' lead development candidate, PALSONIFY, is the first investigational once-daily, oral, selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist that has completed Phase 3 clinical development for acromegaly and is in Phase 3 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It was designed to be a once-daily oral option for the control of acromegaly and carcinoid syndrome. In Phase 3 studies, once-daily, oral PALSONIFY maintained IGF-1 levels and symptom control in patients with acromegaly who were switched from monthly injectable medications (PATHFNDR-1) and rapidly decreased IGF-1 levels and symptom burden in medically untreated acromegaly patients (PATHFNDR-2). IGF-1 is the primary biomarker endocrinologists use to manage acromegaly patients. Results from a Phase 2 study in carcinoid syndrome demonstrated rapid and sustained reductions in flushing episodes and bowel movement frequency, which are the most common symptoms of carcinoid syndrome, leading to the initiation of a Phase 3 trial for control of carcinoid syndrome in patients with neuroendocrine tumors. About Atumelnant Atumelnant, Crinetics' second investigational compound, is the first once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal gland. Diseases associated with excess ACTH can have significant impact on physical and mental health. Atumelnant has exhibited strong binding affinity for MC2R in preclinical models and has demonstrated suppression of adrenally derived glucocorticoids and androgens that are under the control of ACTH. Data from a 12-week Phase 2 study demonstrated compelling treatment benefits of atumelnant, evidenced by the rapid, substantial and sustained statistically significant reductions in key CAH disease related biomarkers, including androstenedione and 17-hydroxyprogesterone, in a diverse population. Atumelnant is in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with the Phase 3 CALM-CAH trial and a Phase 1/2b trial in ADCS currently enrolling patients. About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. All of the company's drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the plans and timelines for the clinical development of atumelnant and paltusotine, including the therapeutic potential and clinical benefits or safety profile thereof; the plans and timelines for the commercial launch PALSONIFY if approved; the potential clinical benefits of our TSHR antagonist, CRN12755, in patients across multiple indications, and the anticipated timing of clinical trials, registration applications or the therapeutic potential for our development candidates. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential,' 'upcoming' or 'continue' or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, initial or topline data that we report may change following completion or a more comprehensive review of the data related to the clinical studies and such data may not accurately reflect the complete results of a clinical study, and the FDA and other regulatory authorities may not agree with our interpretation of such results; geopolitical events may disrupt Crinetics' business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity; the success of Crinetics' clinical studies and nonclinical studies; regulatory developments in the United States and foreign countries; clinical studies and preclinical studies may not proceed at the time or in the manner expected, or at all; the timing and outcome of research, development and regulatory review is uncertain, and Crinetics' drug candidates may not advance in development or be approved for marketing; and the other risks and uncertainties described in the Company's periodic filings with the Securities and Exchange Commission (SEC). The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading 'Risk Factors' in Crinetics' periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2024 and quarterly report on Form 10-Q for the quarter ended March 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: Media: Natalie Badillo Head of Corporate Communications [email protected] (858) 345-6075
UPI
25-06-2025
- Health
- UPI
Study finds autoimmune diseases increase risk of mood disorders
People living with an autoimmune disease are nearly twice as likely to suffer from mood problems like depression, anxiety or bipolar disorder, a new large-scale study says. Photo by Adobe Stock/HealthDay News People living with an autoimmune disease are nearly twice as likely to suffer from mood problems like depression, anxiety or bipolar disorder, a new large-scale study says. The risk of mood disorders is 87% to 97% higher in people suffering from rheumatoid arthritis, inflammatory bowel disease, lupus, multiple sclerosis, psoriasis and Graves' syndrome, researchers reported Tuesday in the BMJ Mental Health. This risk remains higher even after accounting for other factors like age, income and family history of psychiatric disorders, researchers found. "Together, these results support the hypothesis that exposure to chronic inflammation may be associated with a greater risk for affective disorders," concluded the research team led by Arish Mudra Rakshasa-Loots with the University of Edinburgh Center for Clinical Brain Sciences in Britain. For the study, researchers drew on data from 1.5 million people participating in a new large-scale British health study. Upon recruitment to the ongoing study, people provided a history of their physical and mental health. In all, more than 37,800 of the study participants reported living with an autoimmune condition. About 29% of people with an autoimmune illness said they'd been previously diagnosed with a mood disorder, compared with 18% of the general population, results show. This included more than 25% versus 15% diagnosed with depression, and 21% versus nearly 13% diagnosed with anxiety. Women with autoimmune diseases were particularly vulnerable to mood disorders, affecting 32% compared with 21% among men, results show. "Theories suggest that sex hormones, chromosomal factors, and differences in circulating antibodies may partly explain these sex differences," researchers wrote. Women with depression tend to have higher levels of inflammatory chemicals in their bloodstream, researchers noted. "It is therefore possible that women may experience the compounding challenges of increased occurrence of autoimmunity and stronger effects of immune responses on mental health, resulting in the substantially higher prevalence of affective disorders observed in this study," the team wrote. Given these results, it might be worth regularly checking people with an autoimmune disease for mood disorders, researchers concluded. "Regular screening for mental health conditions may be integrated into clinical care for people who are diagnosed with autoimmune diseases, and especially women with these diagnoses, to enable early detection of affective disorders and delivery of tailored mental health interventions," researchers wrote. Further studies should be done to determine other problems linked to autoimmune diseases -- like chronic pain, fatigue, sleep disruptions and social isolation - contribute to the risk for mood disorders, researchers added. More information The U.S. Pain Foundation has more on autoimmune diseases and mental health. Copyright © 2025 HealthDay. All rights reserved.
Yahoo
16-06-2025
- Entertainment
- Yahoo
Erin Moriarty of 'The Boys' has Graves' disease: 'Felt the light coming back on' with treatment
Erin Moriarty, the outspoken and righteous Starlight of "The Boys," is speaking out about her health, specifically her ongoing battle with an autoimmune disorder. Moriarty, 30, revealed to her Instagram followers on Friday that she was diagnosed last month with Graves' disease, an autoimmune disorder in which the thyroid becomes overactive. In the caption of her post, Moriarty expresses the positive effects of treatment but reveals the disorder could have been identified earlier "if I hadn't chalked it all up to stress and fatigue." The "Jessica Jones" and "One Life to Live" actor shared a carousel of photos including text message exchanges with her parents. In one screenshot Moriarty tells her mother "I really need relief" as she details her discomfort. "I can't live like this forever," she writes. "It's not just fatigue — it's an ineffable, system wide cry for help and I don't know how long I can remain in this state," Moriarty continues in her text to her mother. Read more: Eric Dane is angry about ALS: There's 'a good chance' he'll die while daughters are young Moriarty did not reveal too much about her symptoms, noting in her caption that "autoimmune disease manifests differently in everybody/every body." According to the Mayo Clinic, symptoms of Graves' disease can include "feeling nervous or irritable," slight tremors of the hands or fingers, weight loss, menstrual changes and heart palpitations. Wendy Williams, Daisy Ridley and Missy Elliott have also spoken publicly about living with Graves' disease. "Within 24 hours of beginning treatment, I felt the light coming back on," Moriarty said in her caption. "It's been increasing in strength ever since." She did not reveal the details of her treatment, but Moriarty told her father in a text message, "I already feel a world of a difference" and that she has since been thinking, "'Damn, this is how I'm supposed to feel? I've been missing out!'" Read more: Miley Cyrus, on the verge of a new era, reveals 'traumatic' health scare: 'excruciating' Since "The Boys" premiered on Prime Video in 2019, Moriarty has starred as superhero Annie January, a.k.a. Starlight, who possesses the power to fly and manipulate light. Without spoiling too much about the series, it now seems Moriarty knows what it's like to lose her spark on- and off-screen — and how to get it back. She concluded her post by urging followers to listen to their bodies and seek medical attention when something feels off. "If [your light] is dimming, even slightly, go get checked," she said. "Don't 'suck it up' and transcend suffering; you deserve to be comfy. S—'s hard enough as is." Sign up for Screen Gab, a free newsletter about the TV and movies everyone's talking about from the L.A. Times. This story originally appeared in Los Angeles Times.
Yahoo
16-06-2025
- Health
- Yahoo
The Boys' Erin Moriarty Shares Graves' Disease Diagnosis on Instagram
The Boys star Erin Moriarty recently opened up about her battle with Graves' disease on Instagram. The actress, who plays Starlight in Amazon Prime's hit superhero series, shared how the autoimmune condition impacted her health and emphasized the critical importance of early diagnosis. Moriarty warned that autoimmune conditions like Graves' disease can significantly diminish one's well-being when left untreated but stressed that proper medical care can lead to significant recovery. Erin Moriarty is candid about her experience with Graves' disease as she shared her journey on Instagram. The actress shared that she was diagnosed with Graves' disease 'a month ago' and noticed a difference 'within 24 hours' of starting treatment. As per Mayo Clinic, 'Graves' disease is an immune system condition that affects the thyroid gland. It causes the body to make too much thyroid hormone. That condition is called hyperthyroidism.' The condition can affect several organs in the body. Moriarty addressed the complicated nature of autoimmune conditions in her Instagram post. The True Detective star explained, 'Autoimmune disease manifests differently in everybody/every body. Your experience will be different from mine.' Moriarty urged her followers not to delay seeking help as she did initially. The actress confessed, 'One thing I can say: if I hadn't chalked it all up to stress and fatigue, I would've caught this sooner. A month ago, I was diagnosed with Graves' disease. Within 24 hours of beginning treatment, I felt the light coming back on.' The actress went on an optimistic description of her progress and recovery. The 30-year-old Red Widow star gushed, 'It's been increasing in strength ever since. If yours is dimming, even slightly, go get checked. Don't 'suck it up' and transcend suffering; you deserve to be comfy.' Fans loved Moriarty's insightful take on Graves' disease and an effort to create awareness about autoimmune conditions. One user commented under the post, 'So happy you're on the road to healing.' Another fan wrote, 'It's not easy to share your diagnosis.' The post The Boys' Erin Moriarty Shares Graves' Disease Diagnosis on Instagram appeared first on - Movie Trailers, TV & Streaming News, and More.
